United States: CMS Issues Warning On Medicare Part D Billing For Hospice Patients

Last Updated: December 11 2013
Article by Howard J. Young, Eric J. Knickrehm and Jacob J. Harper

Hospices will be expected to be more vigilant in their decisions to cover and pay for prescription medications covered under their Medicare hospice per diem payment.

On December 6, the Centers for Medicare & Medicaid Services (CMS) released a 13-page memorandum (Memorandum) to all Medicare Part D plan sponsors and Medicare hospice providers to clarify the criteria for determining payment responsibility for drugs furnished to Medicare hospice beneficiaries.1 While the policy clarifies the broad care obligations of hospices, the Memorandum is also aimed at Part D sponsors to ensure that their payment decisions for drugs provided to hospice beneficiaries are correct under Medicare policy. The Memorandum also warns hospices about the use of narrow formularies, noting that hospices are required either to ensure that the formularies are sufficiently broad to cover drugs needed for the palliation of their patients' terminal conditions and symptoms or to provide off-formulary medications when appropriate. The net result of this CMS clarification is that hospices will be expected to be more vigilant in their decisions to cover and pay for prescription medications covered under their Medicare hospice per diem payments.


In its Memorandum, with instructions effective on March 1, 2014, CMS expressed concern that drugs, particularly analgesics, covered under the Medicare Part A Hospice per diem payment are being billed inappropriately to the Medicare Part D prescription drug benefit, which in many instances results in duplicate payment to a Medicare hospice. Notably, the Memorandum was issued by CMS's Medicare Part D, Chronic Care, and Program Integrity groups. Through an outside contractor, CMS analyzed 2010 Medicare Part D enrollment and payment statistics, finding that Medicare Part D plans paid claims for analgesics (e.g., pain medication) for 14.9% of hospice beneficiaries. The analysis also demonstrated that the billing for analgesics was concentrated among hospice providers that were primarily for profit, new, and/or rural. In fact, just 10% of hospices nationally accounted for nearly 51% of Medicare Part D claims for pain medications. Of those claims, more than 50% were for hospice beneficiaries residing in nursing facilities.

Clarification of Payment Responsibility

Medicare pays hospices an all-inclusive per diem rate for the provision of all services related to an eligible beneficiary's underlying terminal condition. For instance, if a beneficiary is suffering from pain or illness as a result of the terminal condition, the hospice is required by Medicare to provide medications used for the palliation of the patient's symptoms, and the hospice is responsible under its per diem rate to furnish those drugs related to the patient's terminal illness. However, for conditions unrelated to the beneficiary's terminal illness, the beneficiary is entitled to coverage of curative procedures and medications by traditional Medicare or Part D. CMS has identified an ongoing practice whereby hospices allow contracted pharmacies to bill Part D plans for drugs not on the hospices' formularies, even though financial responsibility for the drugs, if related to a terminal illness, rests on the hospices or the beneficiaries. In its Memorandum, CMS states that it views a hospice's responsibility to provide care as broad and that "hospices are required to provide virtually all the care that is needed by terminally ill individuals." Because the designation of what care is unrelated to a terminal illness is not prescribed by the statute or regulations, but rather is driven by a beneficiary-specific analysis, CMS leaves it to individual hospices and their Medicare Administrative Contractors to make those coverage determinations.

Since 2012, CMS has encouraged Part D sponsors to place prior authorization requirements on four categories of prescription drugs: (1) analgesics, (2) anti-nauseants (anti-emetics), (3) laxatives, and (4) anti-anxiety drugs. It has also authorized pay-and-chase methods of Part D claim adjudication. However, CMS notes that it recently became aware that the duplicative payment issue goes beyond just the four classes of drugs specified in earlier guidance, and that many hospices were not viewing the hospice benefit as holistically as the agency does.

In the policy clarification memorandum, CMS alerts Part D sponsors and hospices that drugs covered under Part D for hospice beneficiaries will be "extremely rare," and "[t]herefore, the sponsor should place beneficiary-level [prior authorization] requirements on all drugs for hospice beneficiaries to determine whether the drugs are coverable under Part D." In those rare instances where a Medicare hospice beneficiary may be prescribed a medication for a condition unrelated to the underlying terminal illness, CMS "expect[s] that the hospice provider or prescriber will immediately provide, to the Part D sponsor, the written documentation necessary to satisfy the [prior authorization]." Because CMS expects Part D coverage of drugs furnished to hospice patients to be rare, it would not expect frequent use of prior authorization by Part D sponsors. Additionally, if hospices are slow to electronically file with CMS contractors the completed hospice Notice of Elections that would have otherwise put Part D sponsors on notice that a beneficiary had elected hospice, a Part D sponsor may seek a refund directly from the hospice without involving the dispensing pharmacy. In instances when a beneficiary agrees to be financially responsible for the furnishing of a nonformulary drug but the drug is nevertheless billed to Part D, the sponsor may seek recovery directly from the beneficiary for the noncovered drug.

CMS Independent Reviewer

CMS is exploring the possibility of incorporating an independent review function as part of the prior authorization process. Specifically, the Memorandum sets forth a mechanism for the resolution of disputes between a hospice provider and a Part D sponsor as to whether a drug is for a condition unrelated to the terminal illness:

  • If the hospice provider and Part D sponsor disagree, then once an independent review process is implemented, either may contact the CMS independent reviewer for a determination of drug payment responsibility.
  • A medical review process would be initiated to determine whether the drug is reasonable and necessary and related to the underlying terminal illness, and thus whether the hospice is responsible for payment. If an item was waived through election of the hospice benefit, it is the beneficiary's responsibility and, if unrelated to the underlying terminal condition, can be paid through the Part D sponsor.

CMS would expect Part D sponsors and hospice providers to accept the independent reviewer determination as "binding." The Memorandum notes that the details of the independent review process will be outlined in future guidance. In the interim, however, CMS expects hospices and Part D sponsors to work cooperatively with each other to coordinate benefits and provide and obtain written documentation to fulfill the prior authorization requirements. It also expects Part D sponsors to flag questionable claims and request retrospective determinations of responsibility by the independent reviewer once that process is implemented. Finally, the Memorandum also explains that a beneficiary who disagrees with an independent reviewer's determination may utilize the Medicare fee-for-service appeals process if the determination relates to Part A or B coverage, and the Part D appeals process if the determination relates to Part D coverage.


Ultimately, this CMS policy clarification requires hospice providers to more thoroughly consider and better document whether conditions and prescribed medications are unrelated to underlying terminal illnesses. CMS articulates that because of the human body's interconnectedness, the underlying terminal illness is typically the epidemiological cause of a broad spectrum of presenting symptoms, and the hospice is responsible for providing palliative care for those symptoms. While certain conditions, such as pain caused by a broken bone, may be unrelated in CMS's view, most other symptoms are intended to be treated as part of the Medicare hospice per diem rate. Thus, it is important that hospice providers develop policies, formularies, and robust documentation practices to address medication management related to patients' terminal illnesses. Failure to do so will put hospices at financial risk of refund demands and possibly other program integrity sanctions.


1 View the Memorandum here.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.